Last reviewed · How we verify
NCT06259214
Aesthetic Efficacy of Resin Infiltration Using Different Conditioning Methods: 24-Month Results
NA trial testing 15% HCl gel in White Spot Lesion in 30 participants. Completed in 6 April 2020.
6 January 2019
Quick facts
| Lead sponsor | Ondokuz Mayıs University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 6 January 2017 |
| Primary completion | 6 January 2019 |
| Estimated completion | 6 April 2020 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- 15% HCl gel
- H3PO4 gel
- Er:YAG laser
Conditions studied
- White Spot Lesion — all drugs for White Spot Lesion →
Sponsor
Ondokuz Mayıs University
Who can join
Adults 15 to 19, any sex, with White Spot Lesion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objective: To assess color and fluorescence changes in white spot lesions (WSLs) using different surface conditioning methods prior to resin infiltration: 24-months follow-up Methods: Thirty patients with each at minimum four WSLs after bracket debonding were included. After baseline fluorescence and color measurements, the lesions were randomly divided into four groups (n = 30): G1 (control): regular brushing, G2: 15% HCl gel (Icon Etch), G3: 37% H3PO4 gel (Scotchbond Etchant), G4: Er:YAG laser (Fotona AT Fidelis III). The lesions were desiccated with Icon Dry and then Icon Infiltrant (DMG) was applied. In the treatment groups, color and fluorescence were examined at baseline (T0), just after the resin infiltration treatment (T1), and after 6 (T2) and 24 months (T3). In the control group, the examinations were performed at baseline (T0) and after 6 (T2) and 24 months (T3).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Aesthetic efficacy of resin infiltration on post-orthodontic white spot lesions using different conditioning methods: 24-month randomized control follow-up.
Karaman E, Alan Unsal K, Oz AZ, Oz AA, et al · · 2026 · PMID 41672455 · DOI 10.2319/022825-165.1
Verify or expand the search:
- PubMed search for NCT06259214
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for White Spot Lesion
Currently open trials in the same condition.
- NCT07319884 — The Role of Fluoride Varnish Application in Preventing White Spot Lesions During Clear Aligner Treatment: A Controlled S · NA · active not recruiting
Other Ondokuz Mayıs University trials
Trials by the same sponsor.
- NCT07500389 — Postural Habits, Body Awareness, and Functional Performance Across BMI Categories in Women · not yet recruiting
- NCT07535242 — Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS · not yet recruiting
- NCT07504848 — Stroke Mobility and Caregiver Outcomes · not yet recruiting
- NCT07525557 — Kinesiophobia, Pain and Disability in Chronic Neck Pain · recruiting
- NCT07497802 — Mindfulness-Based Psychoeducation for Women With Gynecological Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06259214 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ondokuz Mayıs University
- Last refreshed: 14 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06259214.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing